Acquisition Synergy Recent acquisition of Cook Biotech by RTI Surgical presents an alignment opportunity to cross-sell regenerative medicine grafts, ECM technologies, and related soft tissue repair solutions to RTI’s customer base and distribution channels.

Regenerative Focus Cook Biotech’s leadership in biologic tissue grafts and ECM technology positions it well to expand partnerships with hospitals and surgical centers seeking advanced regenerative solutions for fistulas, hernias, wounds, and related soft tissue repairs.

Mid-market Footprint With an employee base of 51–200 and annual revenue in the mid eight-figure range, there is room to scale through channel partnerships, contract manufacturers, and regional distributors targeting medium-sized healthcare facilities and specialty surgeons.

Strategic Partnerships Historical collaborations with Sanara MedTech and Aziyo Biologics indicate receptivity to co-development and licensing models; explore new alliances for CanGaroo-like products, antibiotic-infused grafts, or adjunct regenerative platforms.

Technology Enablement Existing tech stack and digital presence (Cloudflare, HubSpot, forms, reCAPTCHA) offer opportunities to accelerate marketing automation, lead capture, and CRM-driven sales cadences to convert hospital procurement and GPO opportunities more efficiently.